免疫功能受损患者因重度急性呼吸窘迫综合征接受体外膜氧合救治的六个月结局:一项国际多中心回顾性研究
该国际多中心回顾性研究纳入10个ICU中2008至2015年因重度ARDS接受ECMO治疗的免疫功能受损患者203例,免疫受损定义为血液系统恶性肿瘤、活动性实体瘤、实体器官移植、获得性免疫缺陷综合征或长期/大剂量糖皮质激素或免疫抑制剂使用。ECMO前PaO2/FiO2中位60 mm Hg,APACHE II中位28分。6个月生存率仅30%,ECMO中位8天、ICU中位25天;血液系统恶性肿瘤患者结局显著更差(log-rank P=0.02)。ECMO相关大出血、插管感染、呼吸机相关性肺炎分别达36%、10%、50%;多因素分析显示免疫缺陷诊断至ECMO插管少于30天与较低6个月死亡率相关(OR 0.32,95%CI 0.16-0.66,P=0.002),较低血小板计数、较高Pco2、年龄和驱动压为独立ECMO前6个月死亡率预测因素。
要点
- 免疫功能受损合并重度ARDS接受ECMO者6个月生存率仅30%,ECMO中位8天、ICU中位25天。
- 血液系统恶性肿瘤患者结局显著更差(log-rank P=0.02)。
- 免疫缺陷诊断至ECMO插管少于30天与较低6个月死亡率相关(OR 0.32,95%CI 0.16-0.66,P=0.002)。
- 较低血小板计数、较高Pco2、年龄和驱动压为独立ECMO前6个月死亡率预测因素。
- ECMO相关大出血36%、插管感染10%、呼吸机相关性肺炎50%。
适用人群与场景
- 纳入2008至2015年10个国际ICU中免疫功能受损且接受ECMO治疗的重度ARDS患者。
- 免疫受损定义为具有血液系统恶性肿瘤、活动性实体瘤、实体器官移植、获得性免疫缺陷综合征,或长期或大剂量糖皮质激素或免疫抑制剂使用。
研究设计与关键结果
- 研究为回顾性多中心研究,纳入10个国际ICU的203例患者,ECMO前APACHE II中位28分(25th-75th百分位20-33),年龄中位51岁(38-59),PaO2/FiO2中位60 mm Hg(50-82)。
- 6个月生存率仅30%,ECMO中位持续时间8天(5-14),ICU中位住院时间25天(16-50)。
- 血液系统恶性肿瘤患者结局显著更差(log-rank P=0.02)。
- ECMO相关大出血、插管感染和呼吸机相关性肺炎分别达36%、10%和50%。
- 多因素分析显示免疫缺陷诊断至ECMO插管少于30天与较低6个月死亡率相关(OR 0.32,95%CI 0.16-0.66,P=0.002)。
- 较低血小板计数、较高Pco2、年龄和驱动压为独立ECMO前6个月死亡率预测因素。
证据类型、等级与局限
- 证据类型:回顾性多中心研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,近期诊断的免疫缺陷与ECMO治疗的重度ARDS患者好得多的预后相关。
- 作者认为,本大型免疫功能受损队列的低6个月生存率支持将ECMO限制于具有现实肿瘤/治疗预后、可接受功能状态和较少ECMO前死亡风险因素的患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Because encouraging rates for hospital and long-term survival of immunocompromised patients in ICUs have been described, these patients are more likely to receive invasive therapies, like extracorporeal membrane oxygenation (ECMO).Objectives: To report outcomes of immunocompromised patients treated with ECMO for severe acute respiratory distress syndrome (ARDS) and to identify their pre-ECMO predictors of 6-month mortality and main ECMO-related complications.Methods: Retrospective multicenter study in 10 international ICUs with high volumes of ECMO cases. Immunocompromised patients, defined as having hematological malignancies, active solid tumor, solid-organ transplant, acquired immunodeficiency syndrome, or long-term or high-dose corticosteroid or immunosuppressant use, and severe ECMO-treated ARDS, from 2008 to 2015 were included.Measurements and Main Results: We collected demographics, clinical data, ECMO-related complications, and ICU- and 6 month-outcome data for 203 patients (median Acute Physiology and Chronic Health Evaluation II score, 28 [25th-75th percentile, 20-33]; age, 51 [38-59] yr; PaO2/FiO2, 60 [50-82] mm Hg before ECMO) who fulfilled our inclusion criteria. Six-month survival was only 30%, with a respective median ECMO duration and ICU stay of 8 (5-14) and 25 (16-50) days. Patients with hematological malignancies had significantly poorer outcomes than others (log-rank P = 0.02). ECMO-related major bleeding, cannula infection, and ventilator-associated pneumonia were frequent (36%, 10%, and 50%, respectively). Multivariate analyses retained fewer than 30 days between immunodeficiency diagnosis and ECMO cannulation as being associated with lower 6-month mortality (odds ratio, 0.32 [95% confidence interval, 0.16-0.66]; P = 0.002), and lower platelet count, higher Pco2, age, and driving pressure as independent pre-ECMO predictors of 6-month mortality.Conclusions: Recently diagnosed immunodeficiency is associated with a much better prognosis in ECMO-treated severe ARDS. However, low 6-month survival of our large cohort of immunocompromised patients supports restricting ECMO to patients with realistic oncological/therapeutic prognoses, acceptable functional status, and few pre-ECMO mortality-risk factors.
参考来源
- Schmidt M, Schellongowski P, Patroniti N, et al. Six-Month Outcome of Immunocompromised Patients with Severe Acute Respiratory Distress Syndrome Rescued by Extracorporeal Membrane Oxygenation. An International Multicenter Retrospective Study. Am J Respir Crit Care Med. 2018. PMID: 29298095. doi:10.1164/rccm.201708-1761OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。